A causal multi-modal AI model was developed to predict personalized chemosensitivity in breast cancer patients using routine pathology and clinical data. Trained on 9,141 patients from nine countries and validated on 1,994 patients from three countries, the model produced treatment-specific recurrence probabilities with near-perfect calibration and strong prognostic discrimination over 5- and 10-year horizons. It outperformed existing recurrence-score tests and could reduce chemotherapy prescriptions by 30% while maintaining recurrence-free rates, with predictive performance also transferring to non-breast cancers.
arXiv:2512.08029v4 Announce Type: replace Abstract: Clinical decision-making in oncology requires forecasting how disease evolves under treatment, yet most AI systems remain static predictors that ca...
arXiv:2606. 25762v1 Announce Type: new Abstract: In oncology, access to patient-level data is often restricted.
arXiv:2607. 04912v1 Announce Type: cross Abstract: In patients with breast cancer, pathological complete response (pCR) has been established as a clinically meaningful surrogate marker for long-term outcomes.
arXiv:2606. 05797v1 Announce Type: new Abstract: Longitudinal treatment decisions require predicting potential outcomes under future treatment sequences in the presence of time-varying confounding, heterogeneous patient dynamics, and limited domain-specific data.
arXiv:2608.24688v1 Announce Type: new Abstract: Precision oncology necessitates a longitudinal model of patient state that captures cancer evolution and treatment over time, integrating multimodal ob...
arXiv:2606. 17405v1 Announce Type: new Abstract: Clinical decision support AI systems (CDSASs) must adapt to evolving patient conditions in real-time while adhering to strict safety constraints.
arXiv:2606. 09898v2 Announce Type: replace Abstract: Cancer treatment involves decisions across multiple clinical outcomes, yet pathway-informed deep learning models are typically evaluated in isolation, making their relative benefits unclear.
arXiv:2606. 02892v1 Announce Type: new Abstract: Breast cancer recurrence, a leading cause of long-term mortality among survivors, requires timely and accurate risk assessment to guide follow-up care and treatment planning.
Accurate prediction of patient-specific therapeutic response from pre-treatment transcriptomes is hindered by the scarcity of matched clinical response labels and post-treatment molecular profiles. Preclinical transfer-learning models can simulate drug-induced expression changes but are often hard to interpret and unstable, whereas knowledge-graph methods provide mechanistic context yet remain static and fail to capture drug-induced transcriptomic perturbation dynamics.
arXiv:2609.14072v1 Announce Type: new Abstract: Large Language Models (LLMs) have displayed impressive capabilities in handling tasks that require few demonstration examples, making them effective fe...
arXiv:2607. 04557v1 Announce Type: cross Abstract: Accurate prediction of patient-specific therapeutic response from pre-treatment transcriptomes is hindered by the scarcity of matched clinical response labels and post-treatment molecular profiles.
arXiv:2606. 09898v1 Announce Type: new Abstract: Cancer treatment planning requires decisions across multiple clinical dimensions at once.